Diabetes in ageing: pathways for developing the evidence base for clinical guidance
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Older adults with diabetes are heterogeneous in their medical, functional and cognitive status, requiring careful individualization of treatment regimens. However, in the absence of detailed information from clinical trials involving older people with varying characteristics, there is a lack of evidence-based guidance which is a significant limitation of current approaches to care. It is important to recognize that older people with diabetes may vary in their profiles according to age category, functional health, presence of frailty and comorbidity profiles. In addition, all older adults with diabetes require an individualized approach to care, ranging from robust individuals to those residing in care homes with limited life expectancy, those requiring palliative care, or end-of-life management. With this background, an International Workshop of experts in the field from multidisciplinary backgrounds set about the important task of identifying key research gaps in areas which may influence large numbers of older adults with diabetes, and in turn, enhance our scientific understanding and their clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
Boyd, C. M., Darer, J., Boult, C., Fried, L. P., Boult, L., & Wu, A. W. (2005) · JAMA · doi:10.1001/jama.294.6.716 · Cited by 2,581
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Cited by
Type 2 diabetes mellitus in older adults: clinical considerations and management
Bellary, S., Kyrou, I., Brown, J. E., & Bailey, C. J. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00512-2 · Cited by 639
Karagiannis, T., Tsapas, A., Athanasiadou, E., Avgerinos, I., Liakos, A., Matthews, D. R., & Bekiari, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108737 · Cited by 146
Boye, K. S., Thieu, V. T., Lage, M. J., Miller, H., & Paczkowski, R. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02106-4 · Cited by 99
Kaveh, M. H., Faradonbeh, M. R., & Kaveh, S. (2024) · Journal of Telemedicine and Telecare · doi:10.1177/1357633x211052222 · Cited by 12
Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
Dadwani, R. S., Wan, W., Skandari, M. R., & Huang, E. S. (2023) · MDM Policy & Practice · doi:10.1177/23814683231187566 · Cited by 8
Self-citation
Metadata
- Authors
- Munshi, M. N., Meneilly, G. S., Rodríguez-Mañas, L., Close, K. L., Conlin, P. R., Cukierman-Yaffe, T., Forbes, A., Ganda, O. P., Kahn, C. R., Huang, E., Laffel, L. M., Lee, C. G., Lee, S., Nathan, D. M., Pandya, N., Pratley, R., Gabbay, R., & Sinclair, A. J.
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 8
- Issue
- 10
- Pages
- 855-867
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W3085703194
- Cited by
- 103
- References
- 43
- FWCI
- 7.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diabetes in ageing: pathways for developing the evidence base for clinical guidance. https://app.cochat.ai/papers/10.1016/s2213-8587(20)30230-8
- The paper
- Munshi, M. N., Meneilly, G. S., Rodríguez-Mañas, L., Close, K. L., Conlin, P. R., Cukierman-Yaffe, T., Forbes, A., Ganda, O. P., Kahn, C. R., Huang, E., Laffel, L. M., Lee, C. G., Lee, S., Nathan, D. M., Pandya, N., Pratley, R., Gabbay, R., & Sinclair, A. J. (2020). Diabetes in ageing: pathways for developing the evidence base for clinical guidance. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(20)30230-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.